+ Watch AMED
on My Watchlist
The Company is a multi-state provider of home health and hospice services.
Amedisys: Caught Between a RAC and a Hard PlacePosted in Citron Reports by CitronResearch on the October 15th, 2009 stock ticker: AMED Citron first reported on Amedisys over a year ago. Never before have we received as much correspondence from former employees as we did after this story. Last month, the market witnessed the abrupt resignations of two key executives from Amedisys. In this post, Citron will shed some light on the “story behind the story” of Amedisys — a story that neither management nor its analysts want to talk about.Amedisys business is providing home health care visits – nurses, hospice workers and therapists – on an outpatient basis. An overwhelming amount of Amedisys’s revenues, in fact 87%, is paid directly by Medicare reimbursement. Under the best of circumstances, this concentration of business would be a significant risk factor. However, for Amedisys, which operates with some of the highest gross and net margins in the business, red flags specific to the company are much more ominous. (more…)
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions